Cytokinetics, Incorporated $CYTK reported second-quarter 2026 revenue of $28.6 million, down sharply from a year earlier but above the consensus estimate of $17.7 million. The company posted a diluted loss per share of ($1.50), narrower than expected, as it continued to operate at a loss while advancing its business.
Profitability remained under pressure in the quarter. Gross loss came in at ($69.2 million), operating loss widened to ($179.2 million), and net loss attributable to common shareholders was ($198.8 million).
Cash usage was significant, with operating cash outflow of ($159.8 million). At the same time, the balance sheet showed a strong cash position of $1.17 billion, while total liabilities stood at $2.10 billion.
- Revenue: $28.6 million
- Diluted EPS: ($1.50)
- Operating loss: ($179.2 million)
- Cash and cash equivalents: $1.17 billion
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Cytokinetics, Incorporated Insider Trading Activity
Cytokinetics, Incorporated insiders have traded $CYTK stock on the open market 49 times in the past 6 months. Of those trades, 0 have been purchases and 49 have been sales.
Here’s a breakdown of recent trading of $CYTK stock by insiders over the last 6 months:
- ANDREW CALLOS (EVP, Chief Commercial Officer) has made 0 purchases and 15 sales selling 136,140 shares for an estimated $9,453,452.
- ROBERT I BLUM (President & CEO) has made 0 purchases and 13 sales selling 112,032 shares for an estimated $7,744,047.
- SUNG LEE (EVP, Chief Financial Officer) has made 0 purchases and 5 sales selling 71,817 shares for an estimated $5,695,855.
- FADY IBRAHAM MALIK (EVP Research & Development) has made 0 purchases and 12 sales selling 43,940 shares for an estimated $3,084,423.
- JOHN T HENDERSON sold 20,000 shares for an estimated $1,519,400
- B LYNNE PARSHALL sold 5,000 shares for an estimated $370,400
- WENDELL WIERENGA sold 4,032 shares for an estimated $302,400
- EDWARD M. MD KAYE sold 2,933 shares for an estimated $223,171
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Cytokinetics, Incorporated Hedge Fund Activity
We have seen 255 institutional investors add shares of Cytokinetics, Incorporated stock to their portfolio, and 177 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AVORO CAPITAL ADVISORS LLC added 3,333,333 shares (+inf%) to their portfolio in Q1 2026, for an estimated $217,399,978
- FMR LLC removed 2,084,612 shares (-16.3%) from their portfolio in Q1 2026, for an estimated $135,958,394
- DEEP TRACK CAPITAL, LP removed 1,962,678 shares (-58.8%) from their portfolio in Q1 2026, for an estimated $128,005,859
- PARADIGM BIOCAPITAL ADVISORS LP added 1,480,857 shares (+inf%) to their portfolio in Q1 2026, for an estimated $96,581,493
- BALYASNY ASSET MANAGEMENT L.P. added 992,545 shares (+inf%) to their portfolio in Q1 2026, for an estimated $64,733,784
- UBS GROUP AG added 945,821 shares (+83.6%) to their portfolio in Q1 2026, for an estimated $61,686,445
- CAPITAL RESEARCH GLOBAL INVESTORS added 770,999 shares (+inf%) to their portfolio in Q1 2026, for an estimated $50,284,554
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Cytokinetics, Incorporated Congressional Stock Trading
Members of Congress have traded $CYTK stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CYTK stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 06/30.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
Cytokinetics, Incorporated Price Targets
Multiple analysts have issued price targets for $CYTK recently. We have seen 13 analysts offer price targets for $CYTK in the last 6 months, with a median target of $103.0.
Here are some recent targets:
- Leonid Timashev from RBC Capital set a target price of $117.0 on 07/07/2026
- Ashwani Verma from UBS set a target price of $115.0 on 06/29/2026
- Salim Syed from Mizuho set a target price of $118.0 on 06/24/2026
- Serge Belanger from Needham set a target price of $102.0 on 06/17/2026
- Eric Joseph from Citigroup set a target price of $99.0 on 05/19/2026
- Tessa Romero from JP Morgan set a target price of $97.0 on 05/12/2026
- Joseph Pantginis from HC Wainwright & Co. set a target price of $140.0 on 05/11/2026
